

# Effect of managed care educational interventions in multiple sclerosis during a period of advancing innovation

Terry Richardson, PharmD, BCACP<sup>1</sup>; Jennifer Leming, BA<sup>1</sup>; Steve Casebeer, MBA<sup>1</sup>

**BACKGROUND**



While few new multiple sclerosis (MS) therapies were approved over the past decade, understanding of the disease—particularly smoldering inflammation and neurodegeneration—advanced significantly. This shift outpaced treatment guideline updates and payer policies, creating a gap between emerging evidence and managed care decision-making. To address this, a multi-year, multi-format continuing education (CE) program was launched to update managed care professionals on MS. The curriculum included consistent outcomes measurements across diverse learning formats. In 2023, the program featured a live AMCP symposium, webcast, on-demand activity, and infographic. The 2024–2025 series added another live symposium with simulcast and a podcast.

**OBJECTIVE**


Evaluate changes in knowledge and competence among managed care professionals regarding evolving MS pathophysiology and therapies, characterize learners and their engagement across formats, and describe payer coverage updates.

**CONCLUSIONS**

CE for managed care professionals can address gaps in disease state knowledge and competence to support payer policy changes in the absence of updated guidelines. Participation across multiple CE activities reflects sustained interest in emerging science. Participation across formats underscores the value of diverse educational interventions in informing payer decision-making during periods of rapid innovation.



Download



Listen



Sponsorship by Sanofi.

AAN = American Academy of Neurology. ECTRIMS/EAN = European Academy of Neurology & European Committee for Treatment and Research in Multiple Sclerosis.

Author affiliations: 1. Impact Education, LLC.